Quintiles has been involved with more than 12 Alzheimer’s disease (AD) trials of potentially disease-modifying drugs that had a significant biomarker component. These trials have enrolled 7,583 patients at 524 unique sites across 31 countries since 2007.

In this podcast, Quintiles’ AD experts Lynne Hughes and Roza Hayduk discuss key findings from their latest white paper, Integrating Biomarkers in Alzheimer’s Disease Trials: Review of Compliance with Biomarker Assessments in Alzheimer’s Disease Clinical Trials.